Amedeo Smart

Free Medical Literature Service

 

Amedeo

Chronic Heart Failure
  Free Subscription

Articles published in
Eur Heart J
    October 2026
  1. YALCIN GD, Meder B
    The power of proteomics: predicting mortality in heart failure.
    Eur Heart J. 2026 Oct 8:ehag721. doi: 10.1093.
    >> Share

  2. ZIZEK D, Ivanovski M, Mrak M, Pestrea C, et al
    Biventricular vs conduction system pacing after atrioventricular node ablation for heart failure with atrial fibrillation: the CONDUCT-AF trial.
    Eur Heart J. 2026 Oct 6:ehag699. doi: 10.1093.
    >> Share

  3. ELBATREEK MH, Li Z, Yu X, Gehred ND, et al
    Semaglutide, independent of weight loss, attenuates cardiac and hepatic remodelling in experimental heart failure with preserved ejection fraction.
    Eur Heart J. 2026 Oct 5:ehag732. doi: 10.1093.
    >> Share

  4. LAOUTARIS ID, Dritsas A, Adamopoulos S
    Training the diaphragm as a pillar of cardiac rehabilitation in heart failure.
    Eur Heart J. 2026 Oct 5:ehag789. doi: 10.1093.
    >> Share

    September 2026
  5. GORI M, Hamatani Y, Claggett BL, Fazzini L, et al
    Heart failure with mid-range or preserved ejection fraction: temporal trends in an individual patient data meta-analysis of trials.
    Eur Heart J. 2026 Sep 26:ehag588. doi: 10.1093.
    >> Share


  6. Correction to: Europe's heart failure landscape: the persistent under-recognition of HFpEF.
    Eur Heart J. 2026 Sep 23:ehag796. doi: 10.1093.
    >> Share

  7. HARADA T, Reddy YNV, Sorimachi H, Naser JA, et al
    Exercise stress echocardiography for diagnosis of heart failure with preserved ejection fraction: a multicentre study.
    Eur Heart J. 2026 Sep 10:ehag716. doi: 10.1093.
    >> Share

  8. CREA F
    Novel risk scores for the prediction of heart failure.
    Eur Heart J. 2026;47:4705-4710.
    >> Share

  9. FINOCCHIARO G, Perotto M, Merlo M, Luscher TF, et al
    Reconciling evidence-based and personalized medicine: perspectives in heart failure and cardiomyopathies.
    Eur Heart J. 2026 Sep 7:ehag596. doi: 10.1093.
    >> Share

  10. PEDICINO D, Volpe M
    Weekly Journal Scan: Simplifying guideline-directed medical therapy with a once-daily polypill improves treatment implementation and short-term outcomes in heart failure with reduced ejection fraction.
    Eur Heart J. 2026 Sep 3:ehag683. doi: 10.1093.
    >> Share

    August 2026
  11. PACKER M, Burkhoff D, Borlaug BA
    Adipose tissue-dependent, left ventricle-independent left atrial myopathy is a primary driver of heart failure with preserved ejection fraction: a hypothesis.
    Eur Heart J. 2026 Aug 30:ehag735. doi: 10.1093.
    >> Share

  12. JOHANSEN ND, Modin D, Pardo-Seco J, Rodriguez-Tenreiro-Sanchez C, et al
    High-dose vs. standard-dose influenza vaccine in heart failure: the FLUNITY-HD trial.
    Eur Heart J. 2026 Aug 29:ehag709. doi: 10.1093.
    >> Share

  13. DOCHERTY KF, Heywood B, Anderson L, Bayes-Genis A, et al
    Personalized evaluation of NT-proBNP and clinical characteristics in suspected heart failure: the PRECISE-HF study.
    Eur Heart J. 2026 Aug 28:ehag686. doi: 10.1093.
    >> Share

  14. KOBER L, Adamo M, Ruwald AC, Tomasoni D, et al
    2026 ESC Guidelines for the management of heart failure.
    Eur Heart J. 2026 Aug 28:ehag100. doi: 10.1093.
    >> Share

  15. ONO R, McMurray JJV
    Potassium in heart failure: prognostic associations and clinical implications.
    Eur Heart J. 2026 Aug 26:ehag666. doi: 10.1093.
    >> Share

  16. LUND LH, Szabo-Soderberg B
    Hypokalaemia and hyperkalaemia in heart failure: risk factor or risk marker?
    Eur Heart J. 2026 Aug 26:ehag664. doi: 10.1093.
    >> Share

  17. HATALA R, Margitfalvi P
    Pursuing physiological resynchronization in heart failure with reduced ejection fraction and left bundle branch block.
    Eur Heart J. 2026 Aug 26:ehag581. doi: 10.1093.
    >> Share

  18. CREA F
    Focus on heart failure: Second Universal Definition, optimal potassium levels, phenotyping of pulmonary hypertension, hereditary transthyretin amyloidosis, and the challenge of a total artificial heart.
    Eur Heart J. 2026;47:4339-4345.
    >> Share

  19. NAIR A, van der Kaaij NP, Kluin J, Rogers J, et al
    Total artificial hearts: an evolution on the horizon.
    Eur Heart J. 2026;47:4396-4409.
    >> Share

  20. PEDICINO D, Volpe M
    Weekly Journal Scan: Revisiting the role of digitalis glycosides in the management of heart failure.
    Eur Heart J. 2026 Aug 20:ehag579. doi: 10.1093.
    >> Share

  21. TOHYAMA T, Ikeda M, Watanabe T, Enzan N, et al
    Temporal comparison of clinical practice and outcomes in heart failure: the JROADHF and JROADHF-NEXT studies.
    Eur Heart J. 2026 Aug 8:ehag577. doi: 10.1093.
    >> Share

  22. LINDE C
    Do women and men have equal benefits from heart failure medications?
    Eur Heart J. 2026 Aug 8:ehag559. doi: 10.1093.
    >> Share

  23. BROWN JM, Cunningham JW
    Mineralocorticoid inhibition in heart failure: does one size fit all?
    Eur Heart J. 2026 Aug 6:ehag603. doi: 10.1093.
    >> Share

  24. JANKOWSKI J, Wu Z
    Paraspeckles, ferroptosis, and cardiac hypertrophy: a new axis in heart failure biology.
    Eur Heart J. 2026 Aug 5:ehag207. doi: 10.1093.
    >> Share

  25. KOBAYASHI M, Pitt B, Zannad F
    Mineralocorticoid receptor overactivation in heart failure with preserved ejection fraction.
    Eur Heart J. 2026 Aug 3:ehag578. doi: 10.1093.
    >> Share

    July 2026
  26. MEYRE PB, Li Y, da Rocha GL, Shemesh E, et al
    Proteomic markers enhance mortality prediction in heart failure.
    Eur Heart J. 2026 Jul 8:ehag525. doi: 10.1093.
    >> Share

  27. CLELAND JGF, Greene SJ, Butler J, van Veldhuisen DJ, et al
    Great debate: medical treatment of heart failure with reduced ejection fraction will rely on four foundational drugs.
    Eur Heart J. 2026 Jul 6:ehag511. doi: 10.1093.
    >> Share

  28. LUND LH, Pitt B
    Brain mineralocorticoid receptor activation and antagonism in heart failure with preserved ejection fraction: a hypothesis.
    Eur Heart J. 2026 Jul 2:ehag450. doi: 10.1093.
    >> Share

    June 2026
  29. WALSH MN, Kober L, Sliwa K, Adamo M, et al
    AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).
    Eur Heart J. 2026 Jun 29:ehag500. doi: 10.1093.
    >> Share

  30. PANDEY A, Usman MS, Subramanian V, Segar MW, et al
    Weight loss, exercise haemodynamics, and health status with incretin therapy for heart failure with preserved ejection fraction and obesity.
    Eur Heart J. 2026 Jun 29:ehag483. doi: 10.1093.
    >> Share

  31. CREA F
    Interaction of heart failure with chronic kidney disease, liver disease and cancer: the need for systems cardiology.
    Eur Heart J. 2026;47:3023-3029.
    >> Share

  32. RAO VS, Ivey-Miranda JB, Cox ZL, Wilson FP, et al
    Blood aldosterone concentrations and effects of mineralocorticoid receptor antagonists in heart failure.
    Eur Heart J. 2026 Jun 16:ehag440. doi: 10.1093.
    >> Share

  33. BUTLER J, Jamil A, Cherney DZI, Jafar TH, et al
    Albuminuria and heart failure.
    Eur Heart J. 2026 Jun 12:ehag426. doi: 10.1093.
    >> Share

  34. PAILLARD M
    ERA4Health funded project: liver-heart crosstalk in heart failure.
    Eur Heart J. 2026 Jun 4:ehag360. doi: 10.1093.
    >> Share

    May 2026
  35. PIEPOLI M, Rosano G, Abreu A, Adamo M, et al
    Prevention of heart failure.
    Eur Heart J. 2026 May 30:ehag362. doi: 10.1093.
    >> Share

  36. ONO R, Chimura M, Docherty KF, Henderson AD, et al
    Optimal serum potassium concentrations in heart failure: an individual patient data meta-analysis.
    Eur Heart J. 2026 May 28:ehag341. doi: 10.1093.
    >> Share

  37. GRAPSA J, Almeida AG, Sambola A, Vitale C, et al
    Women's heart centres: a clinical consensus statement of the European Association of Cardiovascular Imaging (EACVI), the European Association of Percutaneous Cardiovascular Interventions (EAPCI), the Heart Failure Association (HFA), and the Associatio
    Eur Heart J. 2026 May 26:ehag350. doi: 10.1093.
    >> Share

  38. CENKO E, Badimon L, Vadala G, Merkus D, et al
    Pathophysiology, prevention, and management of coronary microvascular obstruction.
    Eur Heart J. 2026 May 26:ehag334. doi: 10.1093.
    >> Share

  39. KIM LY, Yuk JS, Kim BG
    Reproductive history, hormonal exposure, and risk of heart failure in postmenopausal women: a Korean nationwide study.
    Eur Heart J. 2026 May 25:ehag380. doi: 10.1093.
    >> Share

  40. CREA F
    Heart failure and cardiomyopathies: epidemiology, mechanisms, and new therapeutic targets.
    Eur Heart J. 2026;47:2231-2237.
    >> Share

  41. BUTLER J, Khan MS, Friede T, Placzek M, et al
    Mitral transcatheter edge-to-edge repair and outcomes according to baseline health status: the RESHAPE-HF2 trial.
    Eur Heart J. 2026;47:2290-2304.
    >> Share

  42. HEYMANS S
    The dual face of lamin A/C cardiomyopathy: risk prediction of heart failure and arrhythmias.
    Eur Heart J. 2026 May 13:ehag215. doi: 10.1093.
    >> Share

  43. CLELAND JGF, Lainscak M, Pellicori P
    Does the global prevalence of heart failure now exceed 600 million people? From guesswork to evidence.
    Eur Heart J. 2026 May 11:ehag331. doi: 10.1093.
    >> Share

  44. HELSETH R, Claggett BL, Bhatt A, Vardeny O, et al
    Viral respiratory tract infections in heart failure: the FINEARTS-HF trial.
    Eur Heart J. 2026 May 11:ehag384. doi: 10.1093.
    >> Share

  45. BAVENDIEK U, Thomas NH, Maier LS, Berliner D, et al
    Digitoxin in heart failure with reduced ejection fraction according to atrial fibrillation status: the DIGIT-HF trial.
    Eur Heart J. 2026 May 10:ehag379. doi: 10.1093.
    >> Share

  46. VAN DER MEER P, van Veldhuisen DJ, Voordes GHD, Tijssen J, et al
    Blinded withdrawal of randomized treatment with low-dose digoxin or placebo in patients with heart failure: the DECISION trial.
    Eur Heart J. 2026 May 10:ehag385. doi: 10.1093.
    >> Share

  47. NAEIJE R, Ghio S
    Haemodynamic diagnosis of pulmonary vascular disease in heart failure.
    Eur Heart J. 2026 May 6:ehag318. doi: 10.1093.
    >> Share

  48. IACONELLI A, Morsy MI, Friday JM, Pellicori P, et al
    Cancer and heart failure: prevalence, incidence, and prognosis in Scotland.
    Eur Heart J. 2026 May 2:ehag120. doi: 10.1093.
    >> Share

    April 2026
  49. VAN DER BIJL MF, Scholte NTB, van Oortmerssen JAE, Roeters van Lennep JE, et al
    Sex differences in pharmacological treatment of heart failure: a meta-analysis of randomized trials.
    Eur Heart J. 2026 Apr 28:ehag311. doi: 10.1093.
    >> Share


  50. Correction to: Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial.
    Eur Heart J. 2026 Apr 16:ehag107. doi: 10.1093.
    >> Share

  51. BAUERSACHS J, Soltani S
    From prescription to persistence: guideline-recommended medical therapy in heart failure with reduced ejection fraction.
    Eur Heart J. 2026 Apr 16:ehag198. doi: 10.1093.
    >> Share

  52. SANDERS P, Ariyaratnam JP, Stiles MK, Puvrez A, et al
    Cardiac resynchronization therapy with or without atrioventricular node ablation in atrial fibrillation: the CAAN-AF trial.
    Eur Heart J. 2026 Apr 16:ehag206. doi: 10.1093.
    >> Share

  53. LANDSTEINER I, Verwerft J, Belov D, Verbrugge FH, et al
    Heart failure and preserved ejection fraction: pathophysiology, clinical assessment, and management of exercise intolerance.
    Eur Heart J. 2026 Apr 15:ehag175. doi: 10.1093.
    >> Share

  54. AJALA A, Dodiyi-Manuel S, Yousef Z
    Improving heart failure outcomes in Africa: the PASCAR-Cardiff University Africa-HF programme.
    Eur Heart J. 2026 Apr 7:ehag097. doi: 10.1093.
    >> Share

  55. LINDBERG F, Uijl A, Benson L, Valente V, et al
    Heart failure with reduced ejection fraction in Sweden: patient adherence and persistence to quadruple pharmacotherapy prescription.
    Eur Heart J. 2026 Apr 1:ehag199. doi: 10.1093.
    >> Share

  56. HUANG H, Hu Y, Li H, Cheng S, et al
    Left bundle branch vs biventricular pacing: mechanistic insights from a canine model.
    Eur Heart J. 2026;47:1595-1605.
    >> Share

    March 2026
  57. ZOCCALI C, De Caterina R, Tuttle KR, Burnier M, et al
    Pre-heart failure in early chronic kidney disease: clinical epidemiology and treatment.
    Eur Heart J. 2026 Mar 31:ehag220. doi: 10.1093.
    >> Share

  58. REITSMA TH, Lim CE, Gynnild MN, Kaptoge S, et al
    Prediction of incident heart failure in established atherosclerotic cardiovascular disease: the SMART2-HF model.
    Eur Heart J. 2026 Mar 11:ehag153. doi: 10.1093.
    >> Share

  59. TORP-PEDERSEN C, Kragholm KH, Kober L
    Risk Scores for Heart Failure: Powerful for Populations, Problematic for the individual Patient.
    Eur Heart J. 2026 Mar 11:ehag183. doi: 10.1093.
    >> Share


  60. Prediction of incident heart failure in individuals without prior cardiovascular disease: the SCORE2-HF risk model.
    Eur Heart J. 2026 Mar 11:ehag154. doi: 10.1093.
    >> Share

  61. REITSMA TH, Savarese G, Kuzma L, Deo SV, et al
    Risk prediction in patients with heart failure with preserved ejection fraction: the LIFE-Preserved model.
    Eur Heart J. 2026 Mar 11:ehag182. doi: 10.1093.
    >> Share

  62. BORLAUG BA, Zile MR, Packer M
    Visceral adiposity assessment to enhance risk stratification in heart failure with preserved ejection fraction.
    Eur Heart J. 2026 Mar 6:ehag119. doi: 10.1093.
    >> Share

  63. CHARRON P, Proukhnitzky J, Ben Yaou R, Richard P, et al
    Laminopathies: natural history and risk prediction of heart failure.
    Eur Heart J. 2026 Mar 6:ehag104. doi: 10.1093.
    >> Share

  64. JIN K, Tang Y, Zhan J, Zhou Y, et al
    Nuclear AGO2 exacerbates heart failure with preserved ejection fraction through myocardial ketogenesis.
    Eur Heart J. 2026 Mar 5:ehag067. doi: 10.1093.
    >> Share

  65. SANTOVITO D, Weber C
    Argonaute nuclear power: nuclear microRNAs control cardiac metabolism in heart failure with preserved ejection fraction.
    Eur Heart J. 2026 Mar 5:ehaf841. doi: 10.1093.
    >> Share

  66. GALLO G, Volpe M
    Weekly Journal Scan: Estimated efficacy of a combined three-pillar drug treatment in the management of heart failure with mildly reduced or preserved ejection fraction.
    Eur Heart J. 2026 Mar 5:ehag135. doi: 10.1093.
    >> Share

  67. EGOROVA AD
    Addressing the blind spot: identifying heart failure with preserved ejection fraction in adults with congenital heart disease.
    Eur Heart J. 2026 Mar 5:ehag130. doi: 10.1093.
    >> Share

  68. MOURA B, Sousa A, Bayes-Genis A
    Europe's heart failure landscape: the persistent under-recognition of HFpEF.
    Eur Heart J. 2026 Mar 5:ehaf981. doi: 10.1093.
    >> Share

  69. ABA N, Le Teuff G, Fresneau B, Koscielny S, et al
    Transcriptomic biomarkers related to cardiac disease in childhood cancer survivors: a case-control study.
    Eur Heart J. 2026;47:1066-1080.
    >> Share

    February 2026
  70. DE BOER RA, Abdellatif M, Bauersachs J, Roger VL, et al
    Heart failure in the elderly: epidemiology, mechanisms, and management.
    Eur Heart J. 2026 Feb 28:ehag110. doi: 10.1093.
    >> Share

  71. PACKER M
    Causal role of adipose tissue-derived adipokines in the pathogenesis of heart failure with preserved ejection fraction: experimental demonstration as the basis for clinical targeting.
    Eur Heart J. 2026 Feb 27:ehag029. doi: 10.1093.
    >> Share

  72. LUND LH, Maggioni AP, Crespo-Leiro MG, Laroche C, et al
    Outcomes of heart failure with reduced, mildly reduced, or preserved ejection fraction: the ESC HF III registry.
    Eur Heart J. 2026 Feb 25:ehaf1074. doi: 10.1093/eurheartj/ehaf1074.
    >> Share

  73. CREA F
    Heart failure and cardiomypathies: epidemiology and management.
    Eur Heart J. 2026;47:877-882.
    >> Share

  74. DUNCKER D, Marijon E, Bauersachs J
    Sudden cardiac death risk in the early vulnerable phase of heart failure: clarifying the SCD-PROTECT findings.
    Eur Heart J. 2026 Feb 13:ehag054. doi: 10.1093.
    >> Share

  75. CREA F
    Focus on trials: atrial fibrillation, heart failure with reduced ejection fraction, acute coronary syndrome, ischaemic stroke, and renovascular hypertension.
    Eur Heart J. 2026;47:649-654.
    >> Share

  76. BAPTISTA R, Rodrigues AM, Bernardo F, Mendes LL, et al
    Heart failure in the Portuguese population aged >/=50 years: prevalence and phenotypes in the PORTHOS study.
    Eur Heart J. 2026 Feb 5:ehag030. doi: 10.1093.
    >> Share

    January 2026
  77. MAEGAARD ERIKSEN V, Lim CW, Thuraiaiyah J, Bjerre Tarp J, et al
    Heart failure with preserved ejection fraction in adults with congenital heart disease.
    Eur Heart J. 2026 Jan 30:ehag017. doi: 10.1093.
    >> Share

  78. KRANTZ MJ, Senatore F, Psotka MA, Fiuzat M, et al
    Heart Failure Endpoints in FDA Pivotal Trials.
    Eur Heart J. 2026 Jan 30:ehag069. doi: 10.1093.
    >> Share

  79. EMANUELSSON F, Benn M
    GLP-1 receptor agonists and heart failure: insights from human genetics.
    Eur Heart J. 2026 Jan 29:ehaf1058. doi: 10.1093/eurheartj/ehaf1058.
    >> Share

  80. HU Y, Zhao Y, Dai N, Zhou Y, et al
    GLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization.
    Eur Heart J. 2026 Jan 29:ehaf1066. doi: 10.1093/eurheartj/ehaf1066.
    >> Share

  81. RAVEENDRA K, Nadarajah R, Larvin H, Farooq M, et al
    Non-antiarrhythmic pharmacotherapy in cardio-renal-metabolic disease and incident atrial fibrillation: a trial meta-analysis.
    Eur Heart J. 2026 Jan 28:ehag021. doi: 10.1093.
    >> Share

  82. ZHANG J, Jiang H, Liu L, Li X, et al
    Histamine N-methyltransferase upregulation, cardiac hypertrophy, and heart failure.
    Eur Heart J. 2026 Jan 22:ehaf1065. doi: 10.1093/eurheartj/ehaf1065.
    >> Share

  83. COSTANTINO S, Di Venanzio L, Paneni F
    Histamine N-methyltransferase in heart failure: from metabolic signalling to chromatin remodelling.
    Eur Heart J. 2026 Jan 22:ehaf1062. doi: 10.1093/eurheartj/ehaf1062.
    >> Share

  84. BAUERSACHS J, Zieroth S, de Boer RA
    The year in cardiovascular medicine 2025: the top 10 papers in heart failure.
    Eur Heart J. 2026 Jan 16:ehaf1044. doi: 10.1093/eurheartj/ehaf1044.
    >> Share

  85. DOCHERTY KF, Otto CM, McMurray JJV
    Valvular heart failure: evolving pharmacological approaches.
    Eur Heart J. 2026 Jan 13:ehaf1079. doi: 10.1093/eurheartj/ehaf1079.
    >> Share

  86. KIM MC, Ahn JH, Hyun DY, Lim Y, et al
    Complete revascularization timing in ST-segment elevation myocardial infarction and multivessel disease with heart failure: the OPTION-STEMI trial.
    Eur Heart J. 2026 Jan 6:ehaf924. doi: 10.1093.
    >> Share

  87. CREA F
    Heart failure and cardiomyopathies: mechanisms, risk prediction, and new therapeutic targets.
    Eur Heart J. 2026;47:1-5.
    >> Share

    December 2025
  88. PEDICINO D, Liuzzo G
    Weekly Journal Scan: Time to consider influenza vaccination as part of routine heart failure care?
    Eur Heart J. 2025 Dec 19:ehaf932. doi: 10.1093.
    >> Share

  89. ALLIE S, Hahnle J, Sliwa K
    Heart failure in Africa: putting Africa on the map.
    Eur Heart J. 2025 Dec 19:ehaf865. doi: 10.1093.
    >> Share

  90. LAM CSP, Lu Y, Tay WT
    Heart failure and economic resilience: why China's decade-long projection matters.
    Eur Heart J. 2025 Dec 12:ehaf901. doi: 10.1093.
    >> Share

  91. WANG H, Zhou H, Chai K, Yan S, et al
    Heart failure in China: a macroeconomic modelling study of intervention strategies.
    Eur Heart J. 2025 Dec 8:ehaf992. doi: 10.1093.
    >> Share

  92. SHECHTER A, Shechter M
    Magnesium in heart failure: an old ion with new lessons.
    Eur Heart J. 2025 Dec 5:ehaf955. doi: 10.1093.
    >> Share

  93. YIN Y, Costello RB, Fonarow GC, Heidenreich PA, et al
    Oral magnesium and outcomes in US veterans with heart failure.
    Eur Heart J. 2025 Dec 4:ehaf881. doi: 10.1093.
    >> Share

    November 2025
  94. CANNATA A, Packer M
    Vericiguat in heart failure with reduced ejection fraction: being confident in the face of uncertainty.
    Eur Heart J. 2025 Nov 28:ehaf888. doi: 10.1093.
    >> Share

  95. SCHOMMER N, Gendron N, Krauel K, Van Bruggen S, et al
    Neutrophil extracellular traps and peptidylarginine deiminase 4-mediated inflammasome activation link diabetes to cardiorenal injury and heart failure.
    Eur Heart J. 2025 Nov 27:ehaf963. doi: 10.1093.
    >> Share

  96. VAN LINTHOUT S, Matz I, Gonzalez A, Davis J, et al
    Cardiac fibroblasts in myocardial injury and heart failure.
    Eur Heart J. 2025 Nov 25:ehaf902. doi: 10.1093.
    >> Share

  97. TAHARA N, Ohta K, Fukumoto Y
    Papillary muscle 18F-fluorodeoxyglucose uptake in heart failure with recovered ejection fraction: reversible metabolic remodelling mimicking cardiac sarcoidosis.
    Eur Heart J. 2025 Nov 18:ehaf898. doi: 10.1093.
    >> Share

  98. CREA F
    Heart failure: focus on genes, kidney, and sudden death.
    Eur Heart J. 2025;46:4449-4452.
    >> Share

  99. CHEN CW, Saeed D, Woo YJ
    Adult heart transplantation in the USA and Western Europe: state of the art review.
    Eur Heart J. 2025 Nov 10:ehaf880. doi: 10.1093.
    >> Share

  100. HABIBI H, Gatzoulis MA, Brida M
    Heart failure: terminology matters.
    Eur Heart J. 2025 Nov 7:ehaf775. doi: 10.1093.
    >> Share

  101. CONNORS JM, Gustafsson F, Uriel N, Pagani FD, et al
    Withdrawal of aspirin in patients with left ventricular assist device treated with vitamin K antagonists: impact of anticoagulation quality in the randomized ARIES-HM3 trial.
    Eur Heart J. 2025 Nov 7:ehaf745. doi: 10.1093.
    >> Share

  102. SCHUBERT MR, Sinner MF
    Understanding atrial cardiomyopathy: a missing link in the prevention of atrial fibrillation, heart failure, and stroke?
    Eur Heart J. 2025 Nov 6:ehaf832. doi: 10.1093.
    >> Share

  103. FATIMA M, Sheikh S, Ammer Z
    Bridging The Gaps In EMPEROR-Preserved: Toward safer and smarter use of Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction.
    Eur Heart J. 2025 Nov 4:ehaf799. doi: 10.1093.
    >> Share

    October 2025
  104. CREA F
    Improving understanding and management of acute heart failure, myocarditis, pericarditis, amyloidosis, mitochondrial cardiomyopathies, hypertrophic cardiomyopathy, and takotsubo syndrome.
    Eur Heart J. 2025;46:3939-3943.
    >> Share

  105. VAD OB, van Vreeswijk N, Yassin AS, Blaauw Y, et al
    Atrial cardiomyopathy: markers and outcomes.
    Eur Heart J. 2025 Oct 15:ehaf793. doi: 10.1093.
    >> Share

  106. LE POLAIN DE WAROUX JB, De Smet MAJ
    Arrhythmic risk and advanced heart failure in dilated cardiomyopathy: a deadly tango.
    Eur Heart J. 2025 Oct 14:ehaf475. doi: 10.1093.
    >> Share

  107. BRAUNWALD E
    The management of heart failure: a brief look into the future.
    Eur Heart J. 2025 Oct 13:ehaf720. doi: 10.1093.
    >> Share

  108. GARCIA-PAVIA P, Gonzalez-Lopez E, Anderson LJ, Cappelli F, et al
    Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association.
    Eur Heart J. 2025 Oct 7:ehaf710. doi: 10.1093.
    >> Share

    September 2025
  109. SEFEROVIC PM, Metra M, Mullens W
    Heart Failure 2025 Congress: a recent remarkable success in heart failure.
    Eur Heart J. 2025 Sep 26:ehaf619. doi: 10.1093.
    >> Share

  110. GOTTHARDT M
    RNA-binding proteins as therapeutic targets in cardiac fibrosis and heart failure.
    Eur Heart J. 2025 Sep 9:ehaf644. doi: 10.1093.
    >> Share

  111. NEUEN BL, Vaduganathan M
    Glomerular filtration rate slope in heart failure: ready for prime time?
    Eur Heart J. 2025 Sep 9:ehaf643. doi: 10.1093.
    >> Share

  112. MENTE A, Miller V, Yusuf S
    Diet and heart failure: evidence is limited to make recommendations.
    Eur Heart J. 2025 Sep 9:ehaf521. doi: 10.1093.
    >> Share

  113. CREA F
    Myocarditis after COVID-19, sepsis-induced cardiomyopathy, and haemodynamic assessment of heart failure: focus on the myocardium.
    Eur Heart J. 2025;46:3315-3318.
    >> Share

  114. INKER LA, Neuen BL, McCallum W, Vaduganathan M, et al
    Decline in glomerular filtration rate as an endpoint in heart failure clinical trials: challenges and solutions.
    Eur Heart J. 2025 Sep 4:ehaf591. doi: 10.1093.
    >> Share

  115. PEIKERT A, Fontana M, Solomon SD, Thum T, et al
    Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment.
    Eur Heart J. 2025 Sep 2:ehaf524. doi: 10.1093.
    >> Share

  116. PACKER M
    Do obesity and visceral adiposity promote heart failure with reduced ejection fraction?
    Eur Heart J. 2025 Sep 2:ehaf645. doi: 10.1093.
    >> Share

  117. BUTT JH, Solomon SD, McMurray JJV
    Incretin-based therapy for heart failure with reduced ejection fraction: why we need a trial.
    Eur Heart J. 2025 Sep 1:ehaf635. doi: 10.1093.
    >> Share

    August 2025
  118. CHIMURA M, Docherty KF, Jhund PS, Yang M, et al
    Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial.
    Eur Heart J. 2025 Aug 31:ehaf706. doi: 10.1093.
    >> Share

  119. BORLAUG BA, Zile MR, Kramer CM, Litwin SE, et al
    HFpEF-ABA score is a more useful enrichment tool than natriuretic peptides in heart failure with preserved ejection fraction.
    Eur Heart J. 2025 Aug 31:ehaf663. doi: 10.1093.
    >> Share

  120. ANKER MS, Mahabadi AA, Totzeck M, Tewes M, et al
    Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial).
    Eur Heart J. 2025 Aug 30:ehaf705. doi: 10.1093.
    >> Share

  121. BUTLER J, Fioretti F, McMullan CJ, Anstrom KJ, et al
    Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial.
    Eur Heart J. 2025 Aug 30:ehaf655. doi: 10.1093.
    >> Share

  122. ROSSELLO X, Dominguez-Rodriguez A, Latini R, Sanchez PL, et al
    Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial.
    Eur Heart J. 2025 Aug 30:ehaf673. doi: 10.1093.
    >> Share

  123. DOCHERTY KF, Heywood B, Bayes-Genis A, Campbell RT, et al
    Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failure.
    Eur Heart J. 2025 Aug 29:ehaf675. doi: 10.1093.
    >> Share

  124. MORA-AYESTARAN N, Ochoa JP, Gomez-Gonzalez C, Navarro-Penalver M, et al
    Arrhythmic genotypes in dilated cardiomyopathy and risk of advanced heart failure.
    Eur Heart J. 2025 Aug 29:ehaf605. doi: 10.1093.
    >> Share

  125. LURZ P, Hahn RT, Kodali S, Makkar R, et al
    Tricuspid valve replacement outcomes by baseline tricuspid regurgitation severity: the TRISCEND II trial.
    Eur Heart J. 2025 Aug 29:ehaf676. doi: 10.1093.
    >> Share

  126. GUALANDRO DM, Masip J, Halvorsen S, Price S, et al
    Acute heart failure in non-cardiac surgery.
    Eur Heart J. 2025 Aug 21:ehaf559. doi: 10.1093.
    >> Share


  127. Correction to: Telemonitoring for heart failure: a meta-analysis.
    Eur Heart J. 2025 Aug 21:ehaf509. doi: 10.1093.
    >> Share

  128. ABDIN A, Sawan N, Katbeh A
    Uniting for heart failure awareness in Syria.
    Eur Heart J. 2025 Aug 21:ehaf500. doi: 10.1093.
    >> Share

  129. CREA F
    Comprehensive update on heart failure and cardiomyopathies: from epidemiology to mechanisms and management.
    Eur Heart J. 2025;46:3027-3031.
    >> Share

  130. SEGAN L, Kistler PM, Nanayakkara S, Taylor A, et al
    Withdrawal of heart failure therapy after atrial fibrillation rhythm control with ejection fraction normalization: the WITHDRAW-AF trial.
    Eur Heart J. 2025 Aug 12:ehaf563. doi: 10.1093.
    >> Share

  131. ADAMO M, Pagnesi M, Ajmone Marsan N, Bauersachs J, et al
    Heart failure with reduced ejection fraction and ventricular secondary mitral regurgitation: a holistic approach.
    Eur Heart J. 2025 Aug 1:ehaf480. doi: 10.1093.
    >> Share

    July 2025
  132. KOBAYASHI M, Bayes-Genis A, Duarte K, McMurray JJV, et al
    Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction.
    Eur Heart J. 2025 Jul 30:ehaf457. doi: 10.1093.
    >> Share


  133. Correction to: Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial.
    Eur Heart J. 2025 Jul 24:ehaf512. doi: 10.1093.
    >> Share

  134. KANEKO T, Kagiyama N, Okazaki S, Amano M, et al
    Transcatheter edge-to-edge repair vs medical therapy in atrial functional mitral regurgitation: a propensity score-based comparison from the OCEAN-Mitral and REVEAL-AFMR registries.
    Eur Heart J. 2025 Jul 9:ehaf511. doi: 10.1093.
    >> Share

  135. GIANNAKOULAS G, Farmakis IT, Hobohm L, Verbrugge FH, et al
    Acute right ventricular failure: pathophysiology, aetiology, assessment, and management.
    Eur Heart J. 2025;46:2520-2535.
    >> Share

  136. CREA F
    Heart failure: evolving management and new therapeutic targets.
    Eur Heart J. 2025;46:2359-2363.
    >> Share

  137. HEIMERL M, Erschow S, Muller-Olling M, Manstein DJ, et al
    Cardiac dysfunction related to cardiac mRNA and protein traffic impairment due to reduced unconventional motor protein myosin-5b expression.
    Eur Heart J. 2025;46:2437-2454.
    >> Share

    June 2025
  138. LI Y, Wang Y, Zhang C
    Electrical storm and refractory heart failure necessitating left ventricular assist device in ischaemic cardiomyopathy with apical aneurysm.
    Eur Heart J. 2025 Jun 16:ehaf403. doi: 10.1093.
    >> Share

  139. ZEDER K, Mak S, Galie N, Rosenkranz S, et al
    Right heart catheterization in heart failure: indications, interpretation, and pitfalls.
    Eur Heart J. 2025 Jun 16:ehaf322. doi: 10.1093.
    >> Share

  140. LINDE C, Packer M, Bauersachs J
    Great debate: ablation of atrial fibrillation should be performed in patients with heart failure with reduced ejection fraction.
    Eur Heart J. 2025 Jun 10:ehaf182. doi: 10.1093.
    >> Share

  141. RYAN M, Petrie MC, Kontopantelis E, Dodd M, et al
    Medical therapy and outcomes in REVIVED-BCIS2 and STICHES: an individual patient data analysis.
    Eur Heart J. 2025;46:2052-2062.
    >> Share

  142. LI L, Guo J, Feng J, Li T, et al
    Deficiency of the RNA-binding protein RBMS1 improves myocardial fibrosis and heart failure.
    Eur Heart J. 2025 Jun 5:ehaf370. doi: 10.1093.
    >> Share

  143. HAYNES N, Spatz ES
    The invisible costs of heart failure: a societal toll.
    Eur Heart J. 2025 Jun 3:ehaf223. doi: 10.1093.
    >> Share

  144. CHASELING GK, Uchmanowicz I, Back M, Miro O, et al
    Heat extremes and cardiovascular diseases: a scientific statement of the Association of Cardiovascular Nursing & Allied Professions, Association for Acute Cardiovascular Care, European Association of Preventive Cardiology, Heart Failure Association, E
    Eur Heart J. 2025 Jun 3:ehaf326. doi: 10.1093.
    >> Share

  145. NITSCHE C, Dobner S, Rosenblum HR, Patel KP, et al
    Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis.
    Eur Heart J. 2025 Jun 2:ehaf362. doi: 10.1093.
    >> Share

    May 2025
  146. DARVISH M, Shakoor A, Feyz L, Schaap J, et al
    Heart failure: assessment of the global economic burden.
    Eur Heart J. 2025 May 30:ehaf323. doi: 10.1093.
    >> Share

  147. TUAL-CHALOT S, Stellos K
    Unravelling heart failure cellular signalling heterogeneity with spatial transcriptomics.
    Eur Heart J. 2025 May 30:ehaf311. doi: 10.1093.
    >> Share

  148. BAUDRY G, Pereira O, Roubille F, Villaceque M, et al
    Cardiologist follow-up and improved outcomes of heart failure: a French nationwide cohort.
    Eur Heart J. 2025 May 18:ehaf218. doi: 10.1093.
    >> Share

  149. LUND LH
    Heart failure: the need for cardiologist-guided follow-up to improve outcomes.
    Eur Heart J. 2025 May 18:ehaf229. doi: 10.1093.
    >> Share

  150. CREA F
    New treatments and biomarkers in heart failure, hypertrophic cardiomyopathy, and familial hypercholesterolaemia.
    Eur Heart J. 2025;46:1777-1780.
    >> Share

  151. LEE SE, Joo JH, Hwang HS, Chen SF, et al
    Spatial transcriptional landscape of human heart failure.
    Eur Heart J. 2025 May 8:ehaf272. doi: 10.1093.
    >> Share

    April 2025
  152. WIGGERS H
    Fatty acids in heart failure patients: friend or foe?
    Eur Heart J. 2025 Apr 25:ehaf247. doi: 10.1093.
    >> Share

  153. VERBRUGGE FH
    Natriuretic targets in acute heart failure with volume overload: are we misguided?
    Eur Heart J. 2025 Apr 25:ehaf243. doi: 10.1093.
    >> Share

  154. MARQUES P, Ferreira JP
    Obesity, metrics of central adiposity, and prognostic significance in heart failure with preserved and mildly reduced ejection fraction.
    Eur Heart J. 2025 Apr 25:ehaf198. doi: 10.1093.
    >> Share

  155. IVEY-MIRANDA JB, Rao VS, Cox ZL, Moreno-Villagomez J, et al
    Natriuretic response prediction equation for use with oral diuretics in heart failure.
    Eur Heart J. 2025 Apr 24:ehaf268. doi: 10.1093.
    >> Share

  156. MALGIE J, Wilde MI, Brunner-La Rocca HP, Emans ME, et al
    Newly diagnosed heart failure with reduced ejection fraction: timing, sequencing, and titration of guideline-recommended medical therapy.
    Eur Heart J. 2025 Apr 24:ehaf244. doi: 10.1093.
    >> Share

  157. DOCHERTY KF, Shen L, McMurray JJV
    Advocating for better care of patients with heart failure.
    Eur Heart J. 2025 Apr 24:ehaf224. doi: 10.1093.
    >> Share

  158. CREA F
    Focus on heart failure: sex-related differences, new light shed on SGLT2i mechanism of action, and heart failure after myocardial infarction.
    Eur Heart J. 2025;46:1457-1461.
    >> Share

  159. PEDICINO D, Volpe M
    Weekly Journal Scan: a deep insight into aldosterone antagonism across the heart failure spectrum.
    Eur Heart J. 2025 Apr 15:ehaf233. doi: 10.1093.
    >> Share

  160. VELTMANN C, Duncker D, Maier LS
    Management of de novo heart failure with reduced ejection fraction: guideline-recommended medical therapy comes first.
    Eur Heart J. 2025 Apr 9:ehaf157. doi: 10.1093.
    >> Share

  161. AKIN I, Hamdani N, El-Battrawy I
    Multimodal approaches for targeted treatment of heart failure.
    Eur Heart J. 2025 Apr 9:ehaf156. doi: 10.1093.
    >> Share

  162. XIONG G
    Post-capillary pulmonary hypertension in heart failure: addressing statistical and methodological issues in research.
    Eur Heart J. 2025 Apr 8:ehae812. doi: 10.1093.
    >> Share

  163. FAUVEL C, Lamblin N
    Post-capillary Pulmonary Hypertension in Heart Failure is associated with higher mortality and morbidity risk: not just a matter of << hasard >>.
    Eur Heart J. 2025 Apr 8:ehae814. doi: 10.1093.
    >> Share

  164. OSTROMINSKI JW, Hojbjerg Lassen MC, Claggett BL, Miao ZM, et al
    Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney disease.
    Eur Heart J. 2025;46:1321-1331.
    >> Share

    March 2025
  165. SEN P, Sorop O, Merkus D
    Increasing heart rate in heart failure with preserved ejection fraction: a sensible way to go?
    Eur Heart J. 2025 Mar 25:ehaf109. doi: 10.1093.
    >> Share

  166. VAN LOON T, Vernooy K, Lumens J
    Rate acceleration in heart failure with preserved ejection fraction: towards different strokes for different folks.
    Eur Heart J. 2025 Mar 25:ehaf110. doi: 10.1093.
    >> Share

  167. SOUZA ACDAH, Troschel AS, Marquardt JP, Hadzic I, et al
    Skeletal muscle adiposity, coronary microvascular dysfunction, and adverse cardiovascular outcomes.
    Eur Heart J. 2025;46:1112-1123.
    >> Share

  168. CREA F
    Focus on amyloidosis, peripartum cardiomyopathy, and heart failure prediction by artificial intelligence applied to ECG.
    Eur Heart J. 2025;46:987-990.
    >> Share

  169. SLIWA K, Jackson A, Viljoen C, Damasceno A, et al
    Pregnancies in women after peri-partum cardiomyopathy: the global European Society of Cardiology EuroObservational Research Programme Peri-Partum Cardiomyopathy Registry.
    Eur Heart J. 2025;46:1031-1040.
    >> Share

  170. GONZALEZ-LOPEZ E, Maurer MS, Garcia-Pavia P
    Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine.
    Eur Heart J. 2025;46:999-1013.
    >> Share

  171. BOHM M, Butler J, Coats A, Lauder L, et al
    Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
    Eur Heart J. 2025 Mar 4:ehae938. doi: 10.1093.
    >> Share

    February 2025
  172. LINDBERG F, Savarese G
    Opportunities and challenges in preventing heart failure: when is risk modifiable?
    Eur Heart J. 2025 Feb 28:ehaf042. doi: 10.1093.
    >> Share

  173. STORK S
    Suspected heart failure: a clinical pattern that calls for action.
    Eur Heart J. 2025 Feb 25:ehae846. doi: 10.1093.
    >> Share

  174. ABDELLATIF M, Vasques-Novoa F, Trummer-Herbst V, Durand S, et al
    Autophagy is required for the therapeutic effects of the NAD+ precursor nicotinamide in obesity-related heart failure with preserved ejection fraction.
    Eur Heart J. 2025 Feb 25:ehaf062. doi: 10.1093.
    >> Share

  175. GREEN PG, Watson WD, Bussmann BM, De Maria GL, et al
    Metabolic flexibility and reverse remodelling of the failing human heart.
    Eur Heart J. 2025 Feb 25:ehaf033. doi: 10.1093.
    >> Share

  176. DOI S, Reddy YNV, Jensen MD, Smith JR, et al
    Dapagliflozin and ventilatory control during exercise in heart failure with preserved ejection fraction: the CAMEO-DAPA trial.
    Eur Heart J. 2025 Feb 19:ehaf027. doi: 10.1093.
    >> Share

  177. FIORETTI F, Nair AP, Anker SD, Borlaug BA, et al
    Therapeutic left-to-right shunting in heart failure.
    Eur Heart J. 2025 Feb 13:ehaf120. doi: 10.1093.
    >> Share

  178. ANDERSON L, Bayes-Genis A, Bodegard J, Mullin K, et al
    Suspected de novo heart failure in outpatient care: the REVOLUTION HF study.
    Eur Heart J. 2025 Feb 12:ehaf034. doi: 10.1093.
    >> Share

  179. LAKHAL-LITTLETON S
    Anaemia, neurohormonal activation, and myocardial iron depletion in heart failure: can this vicious circle be broken?
    Eur Heart J. 2025 Feb 5:ehae798. doi: 10.1093.
    >> Share

  180. ANGERMANN CE, Sehner S, Gerhardt LMS, Santos-Gallego CG, et al
    Anaemia predicts iron homoeostasis dysregulation and modulates the response to empagliflozin in heart failure with reduced ejection fraction: the EMPATROPISM-FE trial.
    Eur Heart J. 2025 Feb 5:ehae917. doi: 10.1093.
    >> Share

    January 2025
  181. BUTLER J, Hammonds K, Talha KM, Alhamdow A, et al
    Incident heart failure and recurrent coronary events following acute myocardial infarction.
    Eur Heart J. 2025 Jan 28:ehae885. doi: 10.1093.
    >> Share

  182. PEIKERT A, Vaduganathan M, Claggett BL, Kulac IJ, et al
    Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial.
    Eur Heart J. 2025 Jan 28:ehaf057. doi: 10.1093.
    >> Share

  183. MATSUMOTO S, Ohno Y, Noda S, Miyamoto J, et al
    Tricuspid regurgitation and outcomes in mitral valve transcatheter edge-to-edge repair.
    Eur Heart J. 2025 Jan 28:ehae924. doi: 10.1093.
    >> Share

  184. BAUERSACHS J, Zieroth S, de Boer RA
    The year in cardiovascular medicine 2024: the top 10 papers in heart failure.
    Eur Heart J. 2025 Jan 23:ehaf017. doi: 10.1093.
    >> Share

  185. LIUZZO G, Patrono C
    Weekly Journal Scan: Have we reached the SUMMIT of incretin treatment of heart failure with preserved ejection fraction and obesity?
    Eur Heart J. 2025 Jan 21:ehaf013. doi: 10.1093.
    >> Share

  186. GASPERETTI A, Carrick RT, Protonotarios A, Murray B, et al
    Clinical features and outcomes in carriers of pathogenic desmoplakin variants.
    Eur Heart J. 2025;46:362-376.
    >> Share

  187. ANTONIADES C, Chan K
    Using artificial intelligence to spot heart failure from ECGs: is it prime time?
    Eur Heart J. 2025 Jan 15:ehae906. doi: 10.1093.
    >> Share

  188. DHINGRA LS, Aminorroaya A, Sangha V, Pedroso AF, et al
    Heart failure risk stratification using artificial intelligence applied to electrocardiogram images: a multinational study.
    Eur Heart J. 2025 Jan 13:ehae914. doi: 10.1093.
    >> Share

  189. WILKINSON C, Bhatty A, Batra G, Aktaa S, et al
    Definitions of clinical study outcome measures for cardiovascular diseases: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart).
    Eur Heart J. 2025;46:190-214.
    >> Share

    December 2024
  190. VAN ESSEN BJ, Emmens JE, Tromp J, Ouwerkerk W, et al
    Sex-specific risk factors for new-onset heart failure: the PREVEND study at 25 years.
    Eur Heart J. 2024 Dec 30:ehae868. doi: 10.1093.
    >> Share

  191. VAN LOON T, Rijks J, van Koll J, Wolffs J, et al
    Accelerated atrial pacing reduces left-heart filling pressure: a combined clinical-computational study.
    Eur Heart J. 2024;45:4953-4964.
    >> Share

  192. FERREIRA JP, Zannad F, Vasques-Novoa F, Neves JS, et al
    Anaemia, erythrocytosis, and empagliflozin in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
    Eur Heart J. 2024 Dec 6:ehae864. doi: 10.1093.
    >> Share

  193. CREA F
    Focus on adult congenital heart disease and on the role of inflammation and clonal haematopoiesis in heart failure.
    Eur Heart J. 2024;45:4773-4776.
    >> Share

    November 2024
  194. AI L, de Freitas Germano J, Huang C, Aniag M, et al
    Enhanced Parkin-mediated mitophagy mitigates adverse left ventricular remodelling after myocardial infarction: role of PR-364.
    Eur Heart J. 2024 Nov 27:ehae782. doi: 10.1093.
    >> Share

  195. OMEROVIC E, Ramunddal T, Petursson P, Angeras O, et al
    Percutaneous vs. surgical revascularization of non-ST-segment elevation myocardial infarction with multivessel disease: the SWEDEHEART registry.
    Eur Heart J. 2024 Nov 27:ehae700. doi: 10.1093.
    >> Share

  196. MEYER M
    Accelerated pacing as a treatment for heart failure with preserved ejection fraction and atrial fibrillation?
    Eur Heart J. 2024 Nov 26:ehae766. doi: 10.1093.
    >> Share

  197. MAZHAR F, Faucon AL, Fu EL, Szummer KE, et al
    Systemic inflammation and health outcomes in patients receiving treatment for atherosclerotic cardiovascular disease.
    Eur Heart J. 2024;45:4719-4730.
    >> Share


  198. Correction to: Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score.
    Eur Heart J. 2024 Nov 18:ehae818. doi: 10.1093.
    >> Share

  199. EL BEZE N, Steg PG
    Heart failure and revascularization: which method to choose and should we even do it?
    Eur Heart J. 2024 Nov 11:ehae715. doi: 10.1093.
    >> Share

  200. WANDEL S, Desai AS, Chen CW, McMurray JJV, et al
    Centrally adjudicated vs. investigator-reported outcomes in randomized heart failure trials.
    Eur Heart J. 2024 Nov 9:ehae753. doi: 10.1093.
    >> Share

  201. CREA F
    Evolving therapeutic approaches to aortic stenosis, tricuspid regurgitation, hypertrophic cardiomyopathy, and acute heart failure.
    Eur Heart J. 2024;45:4451-4455.
    >> Share

  202. SEFEROVIC PM, Coats AJS, Filippatos G
    The ESC Textbook of Heart Failure: breaking the new educational frontier.
    Eur Heart J. 2024 Nov 6:ehad897. doi: 10.1093.
    >> Share

    October 2024
  203. PEDICINO D, Vergallo R
    Weekly Journal Scan: RESHAPing potential treatment indications for functional mitral regurgitation in heart failure.
    Eur Heart J. 2024 Oct 29:ehae727. doi: 10.1093.
    >> Share

  204. KARAKASIS P, Pamporis K, Siontis KC, Theofilis P, et al
    Major clinical outcomes in symptomatic vs. asymptomatic atrial fibrillation: a meta-analysis.
    Eur Heart J. 2024 Oct 21:ehae694. doi: 10.1093.
    >> Share

  205. TAYLOR J
    New editor-in-chief for European Society of Cardiology heart failure journals.
    Eur Heart J. 2024 Oct 16:ehae644. doi: 10.1093.
    >> Share

  206. MAACK C, Vilahur G, Ruiz-Meana M, Hausenloy D, et al
    New COST Action 'EUropean network to tackle METAbolic alterations in HEART failure' (EU-METAHEART).
    Eur Heart J. 2024 Oct 16:ehae457. doi: 10.1093.
    >> Share

  207. VOLPE M, Galiuto L
    Weekly Journal Scan: FINEARTS-HF supports the role of aldosterone antagonism in the management of heart failure with mildly reduced or preserved ejection fraction.
    Eur Heart J. 2024 Oct 11:ehae679. doi: 10.1093.
    >> Share

  208. CREA F
    New light shed on the treatment of heart failure and on novel therapeutic targets.
    Eur Heart J. 2024;45:3775-3779.
    >> Share

  209. ROSENGREN A
    Loop diuretics in cardiovascular disease: friend or foe?
    Eur Heart J. 2024;45:3850-3852.
    >> Share

    September 2024
  210. TALHA KM, Metra M, Butler J
    Heart failure with preserved ejection fraction: underdiagnosed and undertreated in patients with tricuspid regurgitation.
    Eur Heart J. 2024 Sep 9:ehae544. doi: 10.1093.
    >> Share

  211. HAVERS-BORGERSEN E, Hartwell D, Ekelund C, Butt JH, et al
    Endometriosis and Long-Term Cardiovascular Risk: A Nationwide Danish study.
    Eur Heart J. 2024 Sep 2:ehae563. doi: 10.1093.
    >> Share

    August 2024
  212. BHATT AS, Vaduganathan M
    Implementing Medical Therapy During Worsening Heart Failure.
    Eur Heart J. 2024 Aug 31:ehae566. doi: 10.1093.
    >> Share

  213. TANAKA A, Kida K, Matsue Y, Imai T, et al
    In-hospital initiation of angiotensin receptor-neprilysin inhibition in acute heart failure: the PREMIER trial.
    Eur Heart J. 2024 Aug 31:ehae561. doi: 10.1093.
    >> Share

  214. PASCUAL-FIGAL D, Nunez J, Perez-Martinez MT, Gonzalez-Juanatey JR, et al
    Colchicine in acutely decompensated heart failure: the COLICA trial.
    Eur Heart J. 2024 Aug 30:ehae538. doi: 10.1093.
    >> Share

  215. TARDIF JC, Ouellette K, Boulet J
    Colchicine improves outcomes in coronary disease, but will it in heart failure?
    Eur Heart J. 2024 Aug 30:ehae612. doi: 10.1093.
    >> Share

  216. MINISTRINI S, Tirandi A
    Von Willebrand factor in inflammation and heart failure: beyond thromboembolic and bleeding risk.
    Eur Heart J. 2024 Aug 28:ehae543. doi: 10.1093.
    >> Share

  217. VON HAEHLING S, Doehner W, Evertz R, Garfias-Veitl T, et al
    Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial.
    Eur Heart J. 2024 Aug 26:ehae479. doi: 10.1093.
    >> Share

  218. KITTIPIBUL V, Mentz RJ
    Intravenous iron therapy in heart failure with preserved ejection fraction: how far have we walked?
    Eur Heart J. 2024 Aug 26:ehae490. doi: 10.1093.
    >> Share

  219. REDDY YNV, Melenovsky V, Asokan AK, Haluzik M, et al
    Dapagliflozin, peptide YY, and weight loss in heart failure with preserved ejection fraction.
    Eur Heart J. 2024 Aug 21:ehae534. doi: 10.1093.
    >> Share

  220. MANG G, Chen J, Sun P, Ma R, et al
    Von Willebrand factor exacerbates heart failure through formation of neutrophil extracellular traps.
    Eur Heart J. 2024 Aug 21:ehae517. doi: 10.1093.
    >> Share

  221. CREA F
    Hot topics in thromboembolic risk prevention, heart failure monitoring, and cardiomyopathy risk stratification.
    Eur Heart J. 2024;45:2899-2903.
    >> Share


  222. Correction to: Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial.
    Eur Heart J. 2024 Aug 20:ehae243. doi: 10.1093.
    >> Share

  223. ROSENKRANZ S, Hoeper MM, Maron BA
    Pulmonary hypertension in heart failure: the good, the bad, and the ugly.
    Eur Heart J. 2024 Aug 12:ehae518. doi: 10.1093.
    >> Share

  224. CREA F
    Heart failure and ischaemic heart disease: new challenges and opportunities.
    Eur Heart J. 2024;45:2681-2685.
    >> Share

  225. RIVERO-SANTANA B, Saldana-Garcia J, Caro-Codon J, Zamora P, et al
    Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score.
    Eur Heart J. 2024 Aug 6:ehae496. doi: 10.1093.
    >> Share

    July 2024
  226. FAUVEL C, Damy T, Berthelot E, Bauer F, et al
    Post-capillary pulmonary hypertension in heart failure: impact of current definition in the PH-HF multicentre study.
    Eur Heart J. 2024 Jul 26:ehae467. doi: 10.1093.
    >> Share

  227. OSTROMINSKI JW, Chatur S, Vaduganathan M
    STEPping down diuretic therapy with semaglutide in obesity-related heart failure with preserved ejection fraction: decongestion or disease modification?
    Eur Heart J. 2024 Jul 26:ehae410. doi: 10.1093.
    >> Share

  228. CREA F
    Focus on acute myocardial infarction, sex-related differences in coronary bypass surgery, inflammation in heart failure, and infective endocarditis in prosthetic valves.
    Eur Heart J. 2024;45:2463-2467.
    >> Share

  229. STORK S
    Pulmonary artery pressure-guided heart failure care: the setting matters.
    Eur Heart J. 2024 Jul 19:ehae441. doi: 10.1093.
    >> Share

  230. PEDICINO D, Volpe M
    Weekly Journal Scan: a 'thousand-mile' journey in obesity-related heart failure treatment begins with a few STEPs.
    Eur Heart J. 2024 Jul 10:ehae427. doi: 10.1093.
    >> Share

  231. OSTROMINSKI JW, Solomon SD, Vaduganathan M
    Heart failure with preserved ejection fraction therapy: combining sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists.
    Eur Heart J. 2024 Jul 10:ehae414. doi: 10.1093.
    >> Share

  232. ZANNAD F, Ferreira JP
    Proteomics for understanding progression to heart failure in chronic kidney disease: promising but still not there.
    Eur Heart J. 2024 Jul 9:ehae399. doi: 10.1093.
    >> Share

  233. CREA F
    A new classification of iron-deficient heart failure, sex-related differences in the management of atrial fibrillation and mitral regurgitation, and an update on the genetics of Brugada syndrome.
    Eur Heart J. 2024;45:2267-2270.
    >> Share

  234. CREA F
    Innovative therapeutic targets in cardio-oncology and a Great Debate in heart failure.
    Eur Heart J. 2024;45:2171-2174.
    >> Share

  235. BOROVAC JA
    Guideline-recommended medical therapy for de novo heart failure with reduced ejection fraction: be patient waiting for reverse remodelling.
    Eur Heart J. 2024 Jul 8:ehae400. doi: 10.1093.
    >> Share

  236. BECHER N, Metzner A, Toennis T, Kirchhof P, et al
    Atrial fibrillation burden: a new outcome predictor and therapeutic target.
    Eur Heart J. 2024 Jul 2:ehae373. doi: 10.1093.
    >> Share

    June 2024
  237. HOLFELD J, Nagele F, Polzl L, Engler C, et al
    Cardiac shockwave therapy in addition to coronary bypass surgery improves myocardial function in ischaemic heart failure: the CAST-HF trial.
    Eur Heart J. 2024 Jun 20:ehae341. doi: 10.1093.
    >> Share

  238. VELTMANN C, Duncker D, Doering M, Gummadi S, et al
    Therapy duration and improvement of ventricular function in de novo heart failure: the Heart Failure Optimization study.
    Eur Heart J. 2024 Jun 12:ehae334. doi: 10.1093.
    >> Share

  239. FRIDAY JM, Cleland JG, Pellicori P, Wolters M, et al
    Loop diuretic utilisation with or without heart failure: impact on prognosis.
    Eur Heart J. 2024 Jun 7:ehae345. doi: 10.1093.
    >> Share

  240. CREA F
    Focus on emerging cancer drugs, artificial intelligence applied to imaging, and a new therapeutic target in heart failure.
    Eur Heart J. 2024;45:1959-1962.
    >> Share

  241. BHAVE S, Rodriguez V, Poterucha T, Mutasa S, et al
    Deep learning to detect left ventricular structural abnormalities in chest X-rays.
    Eur Heart J. 2024;45:2002-2012.
    >> Share

  242. ABBAS N, Haas JA, Xiao K, Fuchs M, et al
    Inhibition of miR-21: cardioprotective effects in human failing myocardium ex vivo.
    Eur Heart J. 2024;45:2016-2018.
    >> Share


  243. Correction to: Epidemiology of heart failure in young adults: a French nationwide cohort study.
    Eur Heart J. 2024 Jun 4:ehae187. doi: 10.1093.
    >> Share

    May 2024
  244. PACKER M, Cleland JGF, Bauersachs J
    Great Debate: SGLT2 inhibitors should be first-line treatment in heart failure with reduced ejection fraction.
    Eur Heart J. 2024 May 28:ehae300. doi: 10.1093.
    >> Share

  245. YANO T, Takeda A, Murayama K
    A hidden cause of middle-aged onset heart failure with preserved ejection fraction: a GTPBP3 variant.
    Eur Heart J. 2024 May 24:ehae309. doi: 10.1093.
    >> Share

  246. FEINSTEIN MJ
    Human Immunology of Heart Failure: Deconstructing Inflammatory Risk.
    Eur Heart J. 2024 May 21:ehae339. doi: 10.1093.
    >> Share

  247. SUN J, Yao J, Olen O, Halfvarson J, et al
    Risk of heart failure in inflammatory bowel disease: a Swedish population-based study.
    Eur Heart J. 2024 May 21:ehae338. doi: 10.1093.
    >> Share


  248. Correction to: Anthracycline therapy induces an early decline of cardiac contractility with transient edema in low risk patients with breast cancer.
    Eur Heart J. 2024;45:1764.
    >> Share

  249. DUBIN RF, Deo R, Ren Y, Wang J, et al
    Incident heart failure in chronic kidney disease: proteomics informs biology and risk stratification.
    Eur Heart J. 2024 May 17:ehae288. doi: 10.1093.
    >> Share

  250. AVIERINOS JF, Tribouilloy C, Bursi F, Grigioni F, et al
    Degenerative mitral regurgitation due to flail leaflet: sex-related differences in presentation, management, and outcomes.
    Eur Heart J. 2024 May 16:ehae265. doi: 10.1093.
    >> Share

  251. SHAH SJ, Sharma K, Borlaug BA, Butler J, et al
    Semaglutide and Diuretic Use in Obesity-Related Heart Failure with Preserved Ejection Fraction: A Pooled Analysis of the STEP-HFpEF and STEP-HFpEF-DM trials.
    Eur Heart J. 2024 May 13:ehae322. doi: 10.1093.
    >> Share

  252. PACKER M, Anker SD, Butler J, Cleland JGF, et al
    Identification of three mechanistic pathways for iron-deficient heart failure.
    Eur Heart J. 2024 May 11:ehae284. doi: 10.1093.
    >> Share

  253. CLEPHAS PRD, Zwartkruis VW, Malgie J, van Gent MWF, et al
    Pulmonary artery pressure monitoring in chronic heart failure: effects across clinically relevant subgroups in the MONITOR-HF trial.
    Eur Heart J. 2024 May 11:ehae323. doi: 10.1093.
    >> Share

  254. WANG R, Schiattarella GG
    Tackling metabolic defects in HFpEF.
    Eur Heart J. 2024;45:1494-1496.
    >> Share

    April 2024
  255. NGO LTH, Peng Y, Denman R, Yang I, et al
    Long-term outcomes after hospitalization for atrial fibrillation or flutter.
    Eur Heart J. 2024 Apr 28:ehae204. doi: 10.1093.
    >> Share

  256. JACKSON AM, Goland S, Farhan HA, Yaseen IF, et al
    A novel score to predict left ventricular recovery in peripartum cardiomyopathy derived from the ESC EORP Peripartum Cardiomyopathy Registry.
    Eur Heart J. 2024;45:1430-1439.
    >> Share

  257. PALUDAN-MULLER C, Vad OB, Stampe NK, Diederichsen SZ, et al
    Atrial fibrillation: age at diagnosis, incident cardiovascular events, and mortality.
    Eur Heart J. 2024 Apr 9:ehae216. doi: 10.1093.
    >> Share

  258. CREA F
    The complex interaction between cancer, ischaemic heart disease, and heart failure, and a focus on arrhythmias including risk stratification in Brugada syndrome and leadless pacing.
    Eur Heart J. 2024;45:1183-1187.
    >> Share

  259. RUZIEH M
    Comparative effectiveness research using claims data: meticulous methods don't solve old problems.
    Eur Heart J. 2024;45:1284.
    >> Share

  260. WU VC, Yeh JK, Chen SW, Wu CL, et al
    Syphilis and cardiovascular risk: a Taiwanese registry.
    Eur Heart J. 2024 Apr 3:ehae183. doi: 10.1093.
    >> Share

    March 2024
  261. ALCOCER-GAMBA MA, Alvarez-Sangabriel A, de la Parra-Calderon JA
    Management of heart failure in Mexico: challenges and opportunities.
    Eur Heart J. 2024 Mar 29:ehae059. doi: 10.1093.
    >> Share

  262. PEDICINO D, Volpe M
    Weekly journal scan: a hard RAFTing to improve long-term survival in heart failure with severely reduced ejection fraction.
    Eur Heart J. 2024 Mar 28:ehae167. doi: 10.1093.
    >> Share

  263. WYLD M, Webster AC
    Myocardial infarction and stroke in patients with kidney failure: can we do better?
    Eur Heart J. 2024 Mar 27:ehae153. doi: 10.1093.
    >> Share

  264. SCHUERMANS A, Vlasschaert C, Nauffal V, Cho SMJ, et al
    Clonal haematopoiesis of indeterminate potential predicts incident cardiac arrhythmias.
    Eur Heart J. 2024;45:791-805.
    >> Share

  265. CLELAND JGF, Kalra PA, Pellicori P, Graham FJ, et al
    Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial.
    Eur Heart J. 2024 Mar 6:ehae086. doi: 10.1093.
    >> Share

  266. CHAIX MA, Dore A, Mondesert B, Mongeon FP, et al
    Angiotensin receptor-neprilysin inhibitor vs. placebo in congenital systemic right ventricular heart failure: the PARACYS-RV trial.
    Eur Heart J. 2024 Mar 6:ehad890. doi: 10.1093.
    >> Share

  267. SAYOUR NV, Paal AM, Ameri P, Meijers WC, et al
    Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence.
    Eur Heart J. 2024 Mar 5:ehae105. doi: 10.1093.
    >> Share

  268. MURARU D, Badano LP, Hahn RT, Lang RM, et al
    Atrial secondary tricuspid regurgitation: pathophysiology, definition, diagnosis, and treatment.
    Eur Heart J. 2024 Mar 5:ehae088. doi: 10.1093.
    >> Share


  269. Correction to: Conventional heart failure therapy in cardiac ATTR amyloidosis.
    Eur Heart J. 2024 Mar 1:ehae140. doi: 10.1093.
    >> Share

    February 2024
  270. ZURKAN D, Pitt B, Edelmann F
    Mineralocorticoid receptor antagonists for the prevention of atrial fibrillation in patients with and without heart failure: one more beneficial effect?
    Eur Heart J. 2024 Feb 6:ehae040. doi: 10.1093.
    >> Share

    January 2024
  271. BERNARDO MC, Carvalho SS, Moreira I
    Massive myocardial calcification as an aetiology of heart failure.
    Eur Heart J. 2024 Jan 23:ehae009. doi: 10.1093.
    >> Share

  272. BAUERSACHS J, de Boer RA, Zieroth S
    The year in cardiovascular medicine 2023: the top 10 papers in heart failure and cardiomyopathies.
    Eur Heart J. 2024 Jan 18:ehad878. doi: 10.1093.
    >> Share

  273. GALIUTO L, Volpe M
    A new RNA-interference based strategy is associated with mild beneficial effects in patients with heart failure due to cardiac amyloidosis.
    Eur Heart J. 2024 Jan 18:ehae015. doi: 10.1093.
    >> Share

  274. DOEHNER W, Akyea RK, Ntaios G
    The obesity paradigm on outcome in heart failure with reduced ejection fraction.
    Eur Heart J. 2024 Jan 18:ehad761. doi: 10.1093.
    >> Share

  275. BUTT JH, McMurray JJV
    The obesity paradigm on outcome in heart failure with reduced ejection fraction.
    Eur Heart J. 2024 Jan 18:ehad764. doi: 10.1093.
    >> Share

  276. AHN HJ, An HY, Ryu G, Lim J, et al
    Clonal haematopoiesis of indeterminate potential and atrial fibrillation: an east Asian cohort study.
    Eur Heart J. 2024 Jan 17:ehad869. doi: 10.1093.
    >> Share

  277. PELLICORI P, Hunter D, Ei Khin HH, Cleland JGF, et al
    How to diagnose and treat venous congestion in heart failure.
    Eur Heart J. 2024 Jan 9:ehad883. doi: 10.1093.
    >> Share

  278. ORAII A, Healey JS, Kowalik K, Pandey AK, et al
    Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials.
    Eur Heart J. 2024 Jan 9:ehad811. doi: 10.1093.
    >> Share

  279. KAMBIC T, Lavie CJ, Eijsvogels TMH
    Seeking synergy for novel weight- and glucose-lowering pharmacotherapy and exercise training in heart failure patients with preserved ejection fraction.
    Eur Heart J. 2024 Jan 8:ehad856. doi: 10.1093.
    >> Share

    December 2023

  280. Correction to: Participation in a clinical trial is associated with lower mortality but not lower risk of HF hospitalization in patients with heart failure: observations from the ESC EORP Heart Failure Long-Term Registry.
    Eur Heart J. 2023 Dec 21:ehad855. doi: 10.1093.
    >> Share

  281. ABU-OWN H, Webb I, Okonko DO
    Intravenous iron repletion in heart failure: bridging the gap between symptom relief and hard clinical outcomes.
    Eur Heart J. 2023;44:5092-5094.
    >> Share

  282. KRAMARENKO D, Walsh R
    Emery-Dreifuss muscular dystrophy: a closer look at cardiac complications.
    Eur Heart J. 2023;44:5074-5076.
    >> Share

  283. LI XM, Zhu XJ, Jing ZC
    Reverse cardiac remodelling after balloon atrial septostomy for pulmonary arterial hypertension and end-stage heart failure.
    Eur Heart J. 2023 Dec 16:ehad822. doi: 10.1093.
    >> Share

  284. MULLER FS, Aherrahrou Z, Grasshoff H, Heidorn MW, et al
    Autoantibodies against the chemokine receptor 3 predict cardiovascular risk.
    Eur Heart J. 2023;44:4935-4949.
    >> Share

  285. MEHRA MR, Castagna F, Butler J
    The transformative potential of left ventricular assist devices in advanced heart failure: no more a therapeutic orphan.
    Eur Heart J. 2023 Dec 11:ehad555. doi: 10.1093.
    >> Share

  286. KHAN MS, Usman MS, Van Spall HGC, Greene SJ, et al
    Endpoint adjudication in cardiovascular clinical trials.
    Eur Heart J. 2023;44:4835-4846.
    >> Share

  287. WESTWOOD M, Almeida AG, Barbato E, Delgado V, et al
    Competency-based cardiac imaging for patient-centred care. A statement of the European Society of Cardiology (ESC). With the contribution of the European Association of Cardiovascular Imaging (EACVI), and the support of the Association of Cardiovascul
    Eur Heart J. 2023;44:4771-4780.
    >> Share

    November 2023
  288. SCHMITTO JD, Shaw S, Garbade J, Gustafsson F, et al
    Fully magnetically centrifugal left ventricular assist device and long-term outcomes: the ELEVATE registry.
    Eur Heart J. 2023 Nov 30:ehad658. doi: 10.1093.
    >> Share


  289. Correction to: 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of
    Eur Heart J. 2023 Nov 23:ehad613. doi: 10.1093.
    >> Share

  290. CREA F
    Fighting the pandemic of heart failure: better utilization of current treatments, new drugs, and new therapeutic targets.
    Eur Heart J. 2023;44:4607-4611.
    >> Share

  291. TOMII D, Praz F, Windecker S
    Guideline directed medical therapy in patients with heart failure undergoing transcatheter edge-to-edge mitral valve repair: unfulfilled premise.
    Eur Heart J. 2023 Nov 15:ehad678. doi: 10.1093.
    >> Share

  292. HENRY CM, Oseran AS, Zheng Z, Dong H, et al
    Cardiovascular Hospitalizations and Mortality Among Adults Aged 25 to 64 years in the United States.
    Eur Heart J. 2023 Nov 11:ehad772. doi: 10.1093.
    >> Share

  293. JESSEN N, Mocumbi AO, Sliwa K
    Heart failure in Africa: challenges of dealing with a heterogeneous syndrome in a heterogeneous continent.
    Eur Heart J. 2023 Nov 9:ehad742. doi: 10.1093.
    >> Share

  294. WERT L, Falk V, Potapov EV
    Severe aortic regurgitation after short-term treatment with microaxial left ventricular assist device in the transaxillary approach.
    Eur Heart J. 2023 Nov 9:ehad750. doi: 10.1093.
    >> Share

  295. KIYUNA LA, Candido DS, Bechara LRG, Jesus ICG, et al
    4-Hydroxynonenal impairs miRNA maturation in heart failure via Dicer post-translational modification.
    Eur Heart J. 2023 Nov 7:ehad662. doi: 10.1093.
    >> Share

  296. SLUIJTER JPG, Xiao J
    Post-translational modifications upon mitochondrial dysfunction in heart failure.
    Eur Heart J. 2023 Nov 6:ehad710. doi: 10.1093.
    >> Share

  297. INCIARDI RM, Solomon SD
    Beyond the rhythm: atrial fibrillation, diastolic dysfunction, and heart failure.
    Eur Heart J. 2023 Nov 3:ehad747. doi: 10.1093.
    >> Share

    October 2023
  298. RESTIVO A, Paglianiti DA, D'Amario D
    Left atrial pressure-assisted acute heart failure management in the cardiac intensive care unit: a proof-of-concept.
    Eur Heart J. 2023 Oct 26:ehad730. doi: 10.1093.
    >> Share

  299. LIUZZO G, Patrono C
    Moving a STEP forward in the treatment of patients with obesity and heart failure with preserved ejection fraction.
    Eur Heart J. 2023 Oct 25:ehad674. doi: 10.1093.
    >> Share

  300. CREA F
    Innovative trials in heart failure, dyslipidaemias, and sinus node dysfunction.
    Eur Heart J. 2023;44:4203-4207.
    >> Share

  301. PANDEY A, Kolkailah AA, Cosentino F, Cannon CP, et al
    Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial.
    Eur Heart J. 2023 Oct 21:ehad639. doi: 10.1093.
    >> Share

  302. DENIAU B, Costanzo MR, Sliwa K, Asakage A, et al
    Acute heart failure: current pharmacological treatment and perspectives.
    Eur Heart J. 2023 Oct 18:ehad617. doi: 10.1093.
    >> Share

  303. PEDICINO D, Volpe M
    Atrial fibrillation ablation improves outcomes in patients with end-stage heart failure: is it all gold the glitter in the CASTLE?
    Eur Heart J. 2023 Oct 17:ehad675. doi: 10.1093.
    >> Share

  304. CAI A, Qiu W, Xia S, Zhou Y, et al
    Sex-specific characteristics and outcomes in hospitalized heart failure with preserved ejection fraction: the China Cardiovascular Association Database-Heart Failure Center Registry.
    Eur Heart J. 2023 Oct 4:ehad619. doi: 10.1093.
    >> Share

  305. CREA F
    Focus on heart failure and cardiomyopathies: new ESC Guidelines and key meta-analyses.
    Eur Heart J. 2023;44:3487-3491.
    >> Share

    September 2023
  306. BORLAUG BA, Schaff HV, Asirvatham SJ, Koepp KE, et al
    Surgical pericardiotomy to treat heart failure with preserved ejection fraction: a first clinical study.
    Eur Heart J. 2023 Sep 22:ehad620. doi: 10.1093.
    >> Share

  307. MOHANTY S, La Fazia VM, Natale A
    The Antwerp score: is this the 'new hope on the horizon'?
    Eur Heart J. 2023;44:3336-3338.
    >> Share

  308. PANDEY AK, Bhatt DL, Pandey A, Marx N, et al
    Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction.
    Eur Heart J. 2023 Sep 7:ehad389. doi: 10.1093.
    >> Share

  309. CREA F
    Hot topics in congenital heart disease: tetralogy of Fallot, Ross operation, immunodeficiency, cardiac arrest, and end-stage heart failure.
    Eur Heart J. 2023;44:3201-3204.
    >> Share

  310. LADOUCEUR M
    Congenitally corrected transposition of the great arteries: have we shifted the disease 'trajectory?
    Eur Heart J. 2023;44:3292-3294.
    >> Share

  311. ANGERMANN CE, Ertl G
    Remote heart failure management guided by pulmonary artery pressure home monitoring: rewriting the future?
    Eur Heart J. 2023 Sep 6:ehad525. doi: 10.1093.
    >> Share

  312. BROWNELL NK, Fonarow GC
    Hospitalization for heart failure requires a PROMPT response.
    Eur Heart J. 2023 Sep 6:ehad444. doi: 10.1093.
    >> Share

    August 2023
  313. GHAZI L, Yamamoto Y, Fuery M, O'Connor K, et al
    Electronic health record alerts for management of heart failure with reduced ejection fraction in hospitalized patients: the PROMPT-AHF trial.
    Eur Heart J. 2023 Aug 31:ehad512. doi: 10.1093.
    >> Share

  314. LEONG DP, Joseph P, McMurray JJV, Rouleau J, et al
    Frailty and outcomes in heart failure patients from high-, middle- and low-Income countries.
    Eur Heart J. 2023 Aug 28:ehad595. doi: 10.1093.
    >> Share

  315. CANNIE DE, Syrris P, Protonotarios A, Bakalakos A, et al
    Emery-Dreifuss Muscular Dystrophy 1 is associated with high risk of malignant ventricular arrhythmias and end-stage heart failure.
    Eur Heart J. 2023 Aug 28:ehad561. doi: 10.1093.
    >> Share

  316. MCALISTER FA
    Frailty: A new Vital Sign in Heart Failure Comes of age.
    Eur Heart J. 2023 Aug 28:ehad559. doi: 10.1093.
    >> Share

  317. NASER JA, Lee E, Scott CG, Kennedy AM, et al
    Prevalence and Incidence of Diastolic Dysfunction in Atrial Fibrillation: Clinical Implications.
    Eur Heart J. 2023 Aug 28:ehad592. doi: 10.1093.
    >> Share

  318. VARSHNEY AS, Shah M, Vemulapalli S, Kosinski A, et al
    Heart Failure Medical Therapy Prior to Mitral Transcatheter Edge-to-Edge Repair: The STS/ACC Transcatheter Valve Therapy Registry.
    Eur Heart J. 2023 Aug 26:ehad584. doi: 10.1093.
    >> Share

  319. MERKELY B, Hatala R, Wranicz JK, Duray G, et al
    Upgrade of right ventricular pacing to cardiac resynchronisation therapy in heart failure: a randomised trial.
    Eur Heart J. 2023 Aug 26:ehad591. doi: 10.1093.
    >> Share

  320. LINDE C
    The BUDAPEST trial: a good grade for upgrades in heart failure with reduced ejection fraction.
    Eur Heart J. 2023 Aug 26:ehad588. doi: 10.1093.
    >> Share

  321. PONIKOWSKI P, Mentz RJ, Hernandez AF, Butler J, et al
    Efficacy of Ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis.
    Eur Heart J. 2023 Aug 26:ehad586. doi: 10.1093.
    >> Share

  322. BUENO H, Packer M
    Acetazolamide for Acute Heart Failure: Is ADVOR a Riddle Wrapped in a Mystery Inside an Enigma?
    Eur Heart J. 2023 Aug 25:ehad560. doi: 10.1093.
    >> Share

  323. MEEKERS E, Dauw J, Martens P, Dhont S, et al
    Renal Function and Decongestion With Acetazolamide in Acute Decompensated Heart Failure: The ADVOR Trial.
    Eur Heart J. 2023 Aug 25:ehad557. doi: 10.1093.
    >> Share

  324. MCDONAGH TA, Metra M, Adamo M, Gardner RS, et al
    2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
    Eur Heart J. 2023 Aug 25:ehad195. doi: 10.1093.
    >> Share

  325. WU J, Nadarajah R, Nakao YM, Nakao K, et al
    Temporal trends of cause-specific mortality after diagnosis of atrial fibrillation.
    Eur Heart J. 2023 Aug 25:ehad571. doi: 10.1093.
    >> Share

  326. BAUERSACHS J, Soltani S
    Sodium-glucose co-transporter 2 inhibitors and mineralocorticoid receptor antagonists synergism in heart failure: it takes two to tango.
    Eur Heart J. 2023 Aug 23:ehad540. doi: 10.1093.
    >> Share

  327. BANERJEE M, Maisnam I, Pal R, Mukhopadhyay S, et al
    Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis.
    Eur Heart J. 2023 Aug 22:ehad522. doi: 10.1093.
    >> Share

  328. VAN DISSEL AC, Opotowsky AR, Burchill LJ, Aboulhosn J, et al
    End-stage heart failure in congenitally corrected transposition of the great arteries: a multicentre study.
    Eur Heart J. 2023 Aug 18:ehad511. doi: 10.1093.
    >> Share

  329. CREA F
    Late breaking trials in heart failure.
    Eur Heart J. 2023;44:2877-2882.
    >> Share

  330. MARTENS P, Testani J, Damman K
    Prevention and treatment of diuretic resistance in acute heart failure: when to use which combination of diuretics?
    Eur Heart J. 2023;44:2978-2981.
    >> Share

  331. CHENG RK, Cuddy SAM
    Neurohormonal blockade in transthyretin amyloidosis: perhaps one size does not fit all?
    Eur Heart J. 2023;44:2908-2910.
    >> Share

  332. BAYES-GENIS A, Pascual-Figal D
    Making STRONGer the transition phase: personalized GDMT through NT-proBNP monitoring.
    Eur Heart J. 2023;44:2963-2965.
    >> Share

  333. NADARAJAH R, Nakao YM, Wu J, Gale CP, et al
    Using routinely collected health record data for the earlier detection of heart failure with preserved ejection fraction: FIND-HFpEF.
    Eur Heart J. 2023 Aug 3:ehad440. doi: 10.1093.
    >> Share

  334. LIN GM, Tsai KZ, Lavie CJ
    Waist-to-height ratio for the obesity paradox in heart failure: is it a matter of fitness?
    Eur Heart J. 2023 Aug 2:ehad503. doi: 10.1093.
    >> Share

  335. ROHDE LE, McMurray JJV
    REVIV(E)ing the ischaemic paradigm in heart failure: STICHes are needed.
    Eur Heart J. 2023 Aug 1:ehad488. doi: 10.1093.
    >> Share

    July 2023
  336. PEDICINO D, Volpe M
    New evidence supporting haemodynamics-guided remote management of congestion in heart failure.
    Eur Heart J. 2023 Jul 21:ehad435. doi: 10.1093.
    >> Share

  337. VERGALLO R, Patrono C
    Heart failure and socioeconomic status: global differences and inequalities.
    Eur Heart J. 2023 Jul 15:ehad410. doi: 10.1093.
    >> Share

  338. GREENE SJ, Fonarow GC
    Targeting sacubitril/valsartan for heart failure with mildly reduced or preserved ejection fraction.
    Eur Heart J. 2023 Jul 5:ehad427. doi: 10.1093.
    >> Share


  339. Corrigendum to: Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER.
    Eur Heart J. 2023 Jul 3:ehad406. doi: 10.1093.
    >> Share

    June 2023
  340. BERGONTI M, Ascione C, Marcon L, Pambrun T, et al
    Left ventricular functional recovery after atrial fibrillation catheter ablation in heart failure: a prediction model.
    Eur Heart J. 2023 Jun 30:ehad428. doi: 10.1093.
    >> Share

  341. KOEHLER F, Hindricks G
    Is telemonitoring for heart failure ready after a journey longer than two decades?
    Eur Heart J. 2023 Jun 27:ehad395. doi: 10.1093.
    >> Share

  342. WITSCH J, Kasner SE
    Redefining the role of heart failure in stroke.
    Eur Heart J. 2023 Jun 26:ehad360. doi: 10.1093.
    >> Share

  343. YANG M, Kondo T, Butt JH, Abraham WT, et al
    Stroke in patients with heart failure and reduced or preserved ejection fraction.
    Eur Heart J. 2023 Jun 26:ehad338. doi: 10.1093.
    >> Share

  344. CREA F
    Challenges and opportunities in the management of acute heart failure and cardiac amyloidosis.
    Eur Heart J. 2023;44:2135-2139.
    >> Share

  345. ARNOTT C, Neal B
    Good for your heart and safe for your toes: a patient-level meta-analysis of DAPA-HF and DELIVER.
    Eur Heart J. 2023;44:2184-2186.
    >> Share

  346. TOLOMEO P, Butt JH, Kondo T, Campo G, et al
    Importance of cystatin C in estimating glomerular filtration rate: the PARADIGM-HF trial.
    Eur Heart J. 2023;44:2202-2212.
    >> Share

  347. PEDICINO D, Vergallo R
    Long-lasting effects of transcatheter repair of secondary mitral regurgitation: the latest lesson from COAPT trial.
    Eur Heart J. 2023 Jun 14:ehad349. doi: 10.1093.
    >> Share

  348. JANKOWSKA EA, Ponikowski P
    Acyl-ghrelin therapy for heart failure: already a novel inotrope or even more?
    Eur Heart J. 2023;44:2026-2028.
    >> Share

  349. CREA F
    Addressing the pandemic of heart failure: old and new therapeutic opportunities.
    Eur Heart J. 2023;44:1961-1964.
    >> Share

  350. MARTENS P, Verbrugge FH, Dauw J, Nijst P, et al
    Pre-treatment bicarbonate levels and decongestion by acetazolamide: the ADVOR trial.
    Eur Heart J. 2023;44:1995-2005.
    >> Share

  351. MAHMOOD SS, Riedell PA, Feldman S, George G, et al
    Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients.
    Eur Heart J. 2023;44:2029-2042.
    >> Share

  352. MARTENS P, Yu S, Larive B, Borlaug BA, et al
    Iron deficiency in pulmonary vascular disease: pathophysiological and clinical implications.
    Eur Heart J. 2023;44:1979-1991.
    >> Share

  353. CAMPBELL RT, Docherty KF
    Serum bicarbonate and congestion: a potential biomarker for identifying and guiding management in diuretic resistance?
    Eur Heart J. 2023;44:2006-2008.
    >> Share

  354. MARX N, Muller-Wieland D
    SGLT2 inhibitors in heart failure and type 2 diabetes: from efficacy in trials towards effectiveness in the real world.
    Eur Heart J. 2023 Jun 8:ehad282. doi: 10.1093.
    >> Share

  355. FU EL, Patorno E, Everett BM, Vaduganathan M, et al
    Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study.
    Eur Heart J. 2023 Jun 1:ehad273. doi: 10.1093.
    >> Share

    May 2023

  356. Correction to: The year in cardiovascular medicine 2022: the top 10 papers in heart failure and cardiomyopathies.
    Eur Heart J. 2023 May 24:ehad307. doi: 10.1093.
    >> Share

  357. BUTT JH, Kondo T, Yang M, Jhund PS, et al
    Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER.
    Eur Heart J. 2023 May 23:ehad276. doi: 10.1093.
    >> Share

  358. CHATUR S, Vaduganathan M, Claggett B, Vardeny O, et al
    Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial.
    Eur Heart J. 2023 May 23:ehad283. doi: 10.1093.
    >> Share

  359. BORLAUG BA, Testani JM
    SGLT2 inhibitors and Diuretics in Heart Failure: Clicking Reset on the Renal Volume Setpoint?
    Eur Heart J. 2023 May 23:ehad345. doi: 10.1093.
    >> Share

  360. ADAMO M, Pagnesi M, Mebazaa A, Davison B, et al
    NT-proBNP and high-intensity care for acute heart failure: the STRONG-HF trial.
    Eur Heart J. 2023 May 22:ehad335. doi: 10.1093.
    >> Share

  361. IOANNOU A, Massa P, Patel RK, Razvi Y, et al
    Conventional heart failure therapy in cardiac ATTR amyloidosis.
    Eur Heart J. 2023 May 22:ehad347. doi: 10.1093.
    >> Share

  362. SCHOLTE NTB, Gurgoze MT, Aydin D, Theuns DAMJ, et al
    Telemonitoring for heart failure: a meta-analysis.
    Eur Heart J. 2023 May 22:ehad280. doi: 10.1093.
    >> Share

  363. CLEPHAS PRD, Radhoe SP, Boersma E, Gregson J, et al
    Efficacy of Pulmonary Artery Pressure Monitoring in Patients with Chronic Heart Failure: A Meta-Analysis of Three Randomized Controlled Trials.
    Eur Heart J. 2023 May 21:ehad346. doi: 10.1093.
    >> Share

  364. VADUGANATHAN M, Mentz RJ, Claggett BL, Miao ZM, et al
    Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF.
    Eur Heart J. 2023 May 21:ehad344. doi: 10.1093.
    >> Share

  365. ERN YEOH S, Osmanska J, Petrie MC, Brooksbank KJM, et al
    Dapagliflozin versus metolazone in heart failure resistant to loop diuretics.
    Eur Heart J. 2023 May 21:ehad341. doi: 10.1093.
    >> Share

  366. DAMMAN K
    Risk of knowing too much: the tricky case of estimated glomerular filtration rate and treatment decisions in heart failure.
    Eur Heart J. 2023 May 20:ehad284. doi: 10.1093.
    >> Share

  367. MULLENS W, Schulze PC, Westphal J, Bogoviku J, et al
    Great debate: in patients with decompensated heart failure, acetazolamide in addition to loop diuretics is the first choice.
    Eur Heart J. 2023 May 19:ehad266. doi: 10.1093.
    >> Share


  368. Corrigendum to: Reduced lean body mass: a potential modifiable contributor to the pathophysiology of heart failure.
    Eur Heart J. 2023 May 8:ehad272. doi: 10.1093.
    >> Share

  369. CREA F
    Heart failure with preserved ejection fraction: innovative diagnostic approaches and therapeutic targets.
    Eur Heart J. 2023;44:1481-1485.
    >> Share

  370. LEHTONEN J, Uusitalo V, Poyhonen P, Mayranpaa MI, et al
    Cardiac sarcoidosis: phenotypes, diagnosis, treatment, and prognosis.
    Eur Heart J. 2023;44:1495-1510.
    >> Share

  371. LEE SY, Chang S, Youn JC
    Successful management of aortic root thrombosis in a patient with Heartmate 3.
    Eur Heart J. 2023;44:1578.
    >> Share

    April 2023
  372. XIN Y, Li J, Li H
    Combination diuretic therapy in acute heart failure.
    Eur Heart J. 2023 Apr 21:ehad189. doi: 10.1093.
    >> Share

  373. TRULLAS JC, Casado J, Morales-Rull JL
    Combination diuretic therapy in acute heart failure.
    Eur Heart J. 2023 Apr 21:ehad217. doi: 10.1093.
    >> Share


  374. Erratum to: Iron deficiency in heart failure across the spectrum of left ventricular ejection fraction: dotting the i's.
    Eur Heart J. 2023 Apr 20:ehad232. doi: 10.1093.
    >> Share

  375. JALLOH MB, Granger CB, Fonarow GC, Van Spall HGC, et al
    Multi-level implementation strategies to improve uptake of evidence-based therapies in heart failure.
    Eur Heart J. 2023 Apr 15:ehad150. doi: 10.1093.
    >> Share

  376. SHERROD CF, Farr SL, Sauer AJ
    Overcoming treatment inertia for patients with heart failure: how do we build systems that move us from rest to motion?
    Eur Heart J. 2023 Apr 12:ehad169. doi: 10.1093.
    >> Share

  377. VAN VELDHUISEN DJ, Bauersachs J
    Digitalis in heart failure: declining use and ongoing outcome trials.
    Eur Heart J. 2023 Apr 8:ehad185. doi: 10.1093.
    >> Share

  378. CREA F
    The link among heart failure, chronic kidney disease, and cancer: new light shed on the complex patient.
    Eur Heart J. 2023;44:1099-1102.
    >> Share

    March 2023
  379. LAM CSP, Ho JE
    Do we need dedicated heart failure with preserved ejection fraction clinics?
    Eur Heart J. 2023 Mar 29:ehad172. doi: 10.1093.
    >> Share

  380. SATO R, von Haehling S
    Revisiting the obesity paradox in heart failure: what is the best anthropometric index to gauge obesity?
    Eur Heart J. 2023 Mar 22:ehad079. doi: 10.1093.
    >> Share

  381. BUTT JH, Petrie MC, Jhund PS, Sattar N, et al
    Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox.
    Eur Heart J. 2023 Mar 22:ehad083. doi: 10.1093.
    >> Share

  382. PACKER M, Siddiqi TJ, Butler J
    Drugs that slow the progression of diabetic kidney disease: are renoprotective effects attenuated in heart failure?
    Eur Heart J. 2023 Mar 21:ehad158. doi: 10.1093.
    >> Share

  383. LIUZZO G, Volpe M
    TRANSFORM-HF closes the loop on diuretic therapy in heart failure.
    Eur Heart J. 2023 Mar 21:ehad124. doi: 10.1093.
    >> Share

  384. DIAZ-CANESTRO C, Ng HF, Yiu KH, Montero D, et al
    Reduced lean body mass: a potential modifiable contributor to the pathophysiology of heart failure.
    Eur Heart J. 2023 Mar 16:ehad130. doi: 10.1093.
    >> Share

  385. VERWERFT J, Soens L, Wynants J, Meysman M, et al
    Heart failure with preserved ejection fraction: relevance of a dedicated dyspnoea clinic.
    Eur Heart J. 2023 Mar 16:ehad141. doi: 10.1093.
    >> Share

  386. PEDICINO D, Volpe M
    Improving care for heart failure patients by COACHing clinicians to use decision-support tools.
    Eur Heart J. 2023 Mar 16:ehad097. doi: 10.1093.
    >> Share

  387. RAO VN, Giczewska A, Chiswell K, Felker GM, et al
    Long-term outcomes of phenoclusters in severe tricuspid regurgitation.
    Eur Heart J. 2023 Mar 16:ehad133. doi: 10.1093.
    >> Share

  388. LUND LH, Hage C, Pironti G, Thorvaldsen T, et al
    Acyl ghrelin improves cardiac function in heart failure and increases fractional shortening in cardiomyocytes without calcium mobilization.
    Eur Heart J. 2023 Mar 14:ehad100. doi: 10.1093.
    >> Share

  389. TAYLOR RS, Dalal HM, Zwisler AD
    Cardiac rehabilitation for heart failure: 'Cinderella' or evidence-based pillar of care?
    Eur Heart J. 2023 Mar 11:ehad118. doi: 10.1093.
    >> Share

  390. VERELST FR, Van Craenenbroeck EM, Gevaert AB
    Iron deficiency in heart failure across the spectrum of left ventricular ejection fraction: dotting the i's.
    Eur Heart J. 2023 Mar 9:ehad131. doi: 10.1093.
    >> Share

  391. SHEMESH E, Chevli PA, Islam T, German CA, et al
    Circulating ketone bodies and cardiovascular outcomes: the MESA study.
    Eur Heart J. 2023 Mar 6:ehad087. doi: 10.1093.
    >> Share

  392. KAPELIOS CJ, Benson L, Crespo-Leiro MG, Anker SD, et al
    Participation in a clinical trial is associated with lower mortality but not lower risk of HF hospitalization in patients with heart failure: observations from the ESC EORP Heart Failure Long-Term Registry.
    Eur Heart J. 2023 Mar 4:ehad109. doi: 10.1093.
    >> Share

    February 2023
  393. VOLPE M, Gallo G, Rubattu S
    Endocrine functions of the heart: from bench to bedside.
    Eur Heart J. 2023;44:643-655.
    >> Share

  394. WOUTERS PC, van de Leur RR, Vessies MB, van Stipdonk AMW, et al
    Electrocardiogram-based deep learning improves outcome prediction following cardiac resynchronization therapy.
    Eur Heart J. 2023;44:680-692.
    >> Share

    January 2023
  395. MARK PB, Carrero JJ, Matsushita K, Sang Y, et al
    Major cardiovascular events and subsequent risk of kidney failure with replacement therapy: a CKD Prognosis Consortium study.
    Eur Heart J. 2023 Jan 24:ehac825. doi: 10.1093.
    >> Share

    December 2022
  396. EL-CHOULI M, Meddis A, Christensen DM, Gerds TA, et al
    Lifetime risk of comorbidity in patients with simple congenital heart disease: a Danish nationwide study.
    Eur Heart J. 2022 Dec 7:ehac727. doi: 10.1093.
    >> Share

    November 2022
  397. SCOTTI A, Coisne A, Taramasso M, Granada JF, et al
    Sex-Related Characteristics and Short-Term Outcomes of Patients Undergoing Transcatheter Tricuspid Valve Intervention for Tricuspid Regurgitation.
    Eur Heart J. 2022 Nov 29:ehac735. doi: 10.1093.
    >> Share

  398. HAXHA S, Halili A, Malmborg M, Pedersen-Bjergaard U, et al
    Type 2 diabetes mellitus and higher rate of complete atrioventricular block: a Danish Nationwide Registry.
    Eur Heart J. 2022 Nov 26:ehac662. doi: 10.1093.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016